Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeiGene Ltd (BGNE) and Sunesis Pharma (SNSS).
BeiGene Ltd (BGNE)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on BeiGene Ltd yesterday and set a price target of $170. The company’s shares closed on Friday at $117.62, close to its 52-week low of $105.19.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 11.9% and a 59.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
Currently, the analyst consensus on BeiGene Ltd is a Strong Buy with an average price target of $173.33, which is a 47.4% upside from current levels. In a report issued on June 5, Maxim Group also maintained a Buy rating on the stock with a $170 price target.
See today’s analyst top recommended stocks >>
Sunesis Pharma (SNSS)
In a report released yesterday, Marc Frahm from Cowen & Co. maintained a Hold rating on Sunesis Pharma. The company’s shares closed on Friday at $0.90.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 3.3% and a 54.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Applied Therapeutics Inc.
Sunesis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
